The Cooper Companies, Inc. $COO Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lowered its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 51.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 10,746 shares of the medical device company’s stock after selling 11,310 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Cooper Companies were worth $737,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Cooper Companies by 1.8% during the second quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock worth $1,725,963,000 after buying an additional 421,423 shares during the period. State Street Corp boosted its position in Cooper Companies by 1.2% during the 2nd quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock worth $616,227,000 after purchasing an additional 104,910 shares during the period. Geode Capital Management LLC increased its holdings in Cooper Companies by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock valued at $368,893,000 after purchasing an additional 127,907 shares in the last quarter. Ameriprise Financial Inc. raised its position in Cooper Companies by 98.8% in the second quarter. Ameriprise Financial Inc. now owns 3,388,413 shares of the medical device company’s stock valued at $241,120,000 after purchasing an additional 1,683,561 shares during the period. Finally, Sustainable Growth Advisers LP acquired a new position in shares of Cooper Companies during the second quarter worth about $240,881,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Trading Up 1.6%

NASDAQ COO opened at $82.99 on Monday. The company has a market capitalization of $16.26 billion, a price-to-earnings ratio of 44.14, a price-to-earnings-growth ratio of 2.37 and a beta of 1.03. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $93.00. The company’s fifty day moving average price is $81.83 and its two-hundred day moving average price is $74.84.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the business posted $1.04 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, research analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Holly R. Sheffield acquired 1,230 shares of Cooper Companies stock in a transaction that occurred on Tuesday, December 16th. The shares were purchased at an average cost of $80.75 per share, for a total transaction of $99,322.50. Following the completion of the purchase, the insider directly owned 39,052 shares of the company’s stock, valued at $3,153,449. This trade represents a 3.25% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Maria Rivas bought 1,000 shares of the stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $82.13 per share, with a total value of $82,130.00. Following the purchase, the director owned 11,141 shares of the company’s stock, valued at $915,010.33. The trade was a 9.86% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 16,014 shares of company stock worth $1,304,416. 1.98% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on COO shares. Piper Sandler reiterated an “overweight” rating and set a $94.00 target price (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. Stifel Nicolaus set a $95.00 price objective on shares of Cooper Companies and gave the company a “buy” rating in a research note on Friday, December 5th. The Goldman Sachs Group reissued a “sell” rating and set a $73.00 target price on shares of Cooper Companies in a research report on Friday, January 9th. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. Finally, Barclays set a $98.00 price target on shares of Cooper Companies and gave the stock an “overweight” rating in a research note on Monday, January 26th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $90.77.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.